Related Experiment Video
Updated: Jun 10, 2026
11:29
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Polymorphisms in Toll-like receptor genes--implications for prostate cancer development.
1Department of Urology, "Merkur" University Hospital, Zagreb, Croatia. zeljko.vidas@zg.t-com.hr
Collegium Antropologicum
|August 12, 2010
Summary
Genetic variations in Toll-like receptors (TLRs) may influence prostate cancer risk. Understanding these genetic factors could help identify individuals susceptible to prostate carcinoma development, linking inflammation and cancer.
Area of Science:
- Immunology
- Genetics
- Oncology
Background:
- Toll-like receptors (TLRs) are crucial for innate and adaptive immunity.
- Chronic prostatic inflammation is increasingly linked to benign prostatic hyperplasia and prostate carcinoma.
- Prostatitis correlates with elevated prostate cancer risk, and bacterial colonization is associated with inflammation and cancer.
Purpose of the Study:
- To review key findings on the genetic variability of Toll-like receptor (TLR) genes and their association with prostate cancer risk.
- To explore the role of single nucleotide polymorphisms (SNPs) in TLR genes as potential factors in prostate carcinoma development.
Main Methods:
- Review of existing epidemiological, PCR-based, and genetic studies.
- Analysis of research connecting genetic variability in TLR genes to disease susceptibility.
Main Results:
- Evidence suggests prostate inflammation, potentially driven by factors like bacterial colonization, may contribute to prostate cancer.
- Genetic studies indicate a connection between SNPs in TLR genes and susceptibility to various diseases, including potentially prostate cancer.
Conclusions:
- Identifying genetic factors, such as SNPs in TLR genes, associated with prostate carcinoma risk is a reasonable and important area of investigation.
- Further research into the genetic variability of TLRs can elucidate their role in prostate cancer pathogenesis and susceptibility.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:33Cancer-Critical Genes I: Proto-oncogenes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...